AI-Driven AML Drug Discovery
Accelerating AML Drug Discovery with AI & RNA-Seq
Ligand AI leverages advanced generative models and precision RNA sequencing to identify novel therapeutic targets and small molecules for Acute Myeloid Leukemia.
Discovery Success Rate
3.5x +250%
Time to Phase I
10mo -60%
Genomic Data Points
50B+ Verified
Patent Pending Assets
12 Clinical
How It Works
Our proprietary platform integrates multi-omic data with deep learning to revolutionize the drug development lifecycle for hematologic malignancies.
RNA-Seq Integration
We process massive datasets of RNA sequences from AML patients to identify unique cellular signatures and cryptic splicing events.
Generative AI Models
Our AI designs optimized ligand structures with high binding affinity, targeted specificity, and minimized off-target toxicity profiles.
In-Vitro Validation
In-silico predictions are rapidly validated through automated high-throughput laboratory workflows to confirm biological activity.
Research Focus
Targeting the most challenging mutations in Acute Myeloid Leukemia with AI-driven precision medicine.
Targeted Protein Degradation
Developing PROTACs and molecular glues to eliminate oncogenic proteins previously considered 'undruggable' by standard inhibitors.
Splicing Modulators
Harnessing deep RNA-seq insights to identify and correct aberrant splicing patterns that drive leukemogenesis and drug resistance.
Ready to transform AML drug discovery?
Join leading researchers and biotech innovators using Ligand AI to discover the next generation of precision therapeutics.